The biopharmaceutical company reports positive data from its Phase 2 trial of an immunotherapy for advanced melanoma, showing improved progression-free survival compared to standard of care.
The biopharmaceutical company presents positive Phase 2 data for its lead Immunobody® therapy, showing potential to significantly improve outcomes for late-stage melanoma patients.
The biotechnology company has announced the details for its upcoming Annual General Meeting, where shareholders can attend and hear from the senior management team.
The developer of cancer immunotherapies announces a director has purchased additional shares in the company.
The clinical-stage biotech firm reported positive Phase 2 trial results for its melanoma treatment. However, financial challenges persist with ongoing losses and funding uncertainties beyond 2026.
The biopharmaceutical company will announce its audited results and provide a business update on September 11, 2025.
The developer of cancer immunotherapies announces a director has purchased additional shares in the company.
The developer of cancer immunotherapies announces a director has increased their stake in the company.
The biopharmaceutical company reports strong Phase 2 results for its cancer immunotherapy in late-stage melanoma, demonstrating improved outcomes compared to standard of care.
The biotechnology company is raising funds through a share option exercise, but at a significant 20.5% discount to the previous closing price, signaling low investor appetite.